Oliver Sexton has managed Future Planet Capital's £33m engineering biology fund since 2014, backing platform technologies across therapeutics, agritech, clean biotech, gene editing, and industrial biology, including companies like ArkVax, Synthace, and Tropic Biosciences, while also overseeing exits such as the £85m sale of Quethera to Astellas. His background combines deep scientific training—degrees in molecular biology and plant science plus PhD work in bioremediation—with hands-on commercialization experience from Imperial Innovations and Ark Therapeutics, shaping his approach of helping academic founders build teams and focus on why their technology matters to customers rather than just how it works.